Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Meal Timing and Size Eat 34 smaller meals/day to reduce GI burden
Based on study findings, the risk increases with: Higher doses of medication Longer treatment duration (especially beyond 26 weeks) Very rapid weight loss That same study showed that 47% of acute gallbladder inflammation cases occurred within the first 90 days of starting treatment, which means early monitoring is vital
Primary candidates for GLP-1 therapy include: Patients with type 2 diabetes and inadequate glycemic control despite metformin therapy Individuals with type 2 diabetes and established atherosclerotic cardiovascular disease Patients with type 2 diabetes and multiple cardiovascular risk factors (hypertension, dyslipidemia, obesity) Adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities Patients with metabolic syndrome who have not achieved adequate risk factor control with lifestyle modification For patients with dyslipidemia, GLP-1 agents may be particularly valuable when combined with statin therapy in those who have not reached LDL-C goals or who have persistent hypertriglyceridemia despite statin treatment
Sonju JJ, Dahal A, Singh SS, Jois SD
Don't Fancy a Drink Anymore
2019;14(1):e0210389
US$ 23.34
US$ 25.53
US$ 20.33
US$ 22.02
US$ 27.70
US$ 28.12
US$ 28.74
US$ 20.86
US$ 24.02
US$ 21.21
US$ 26.75
